Keywords: icn, virazole, potential, hep, pharmaceutical, ribavirin, may
ICN's Virazole Potential In Hep C
Article | 08 January 1996
ICN Pharmaceutical's Virazole (ribavirin) may be a safe and efficacious alternative to interferon A therapy in patients with chronic hepatitis ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
